article thumbnail

Lilly and ProQR to expand genetic medicine development agreement

Pharmaceutical Technology

Eli Lilly and Company has expanded a licencing and partnership agreement with ProQR Therapeutics to discover, develop and market new genetic medicines. This alliance is utilising the Axiomer ribonucleic acid (RNA) editing platform of ProQR to address ailments affecting the liver and nervous system.

Genetics 328
article thumbnail

Exsilio debuts with $82M, pitching a ‘leap’ forward for genetic medicine

Bio Pharma Dive

The company claims it can address some of the field’s limitations with medicines delivered via messenger RNA and lipid nanoparticles.

Medicine 299
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Lilly joins RNA editing race with ProQR deal

Bio Pharma Dive

billion, expands Lilly's work in genetic medicine research. An agreement with the Dutch biotech, which could be worth as much as $1.3

RNA 264
article thumbnail

Biology opens up new frontiers in medicine to cure genetic diseases: Kiran Mazumdar Shaw

AuroBlog - Aurous Healthcare Clinical Trials blog

We are witnessing a revolution in healthcare, driven by advances in genetics, Omics, RNA and CRISPR gene-editing technology, to deliver precision and personalised medicine, said Kiran Mazumdar-Shaw, executive chairperson, Biocon and Biocon Biologics. In […]

article thumbnail

CAMP4’s funding influx paves the way for tapping regulatory RNA to treat urea cycle disorders

Pharmaceutical Technology

Last week, CAMP4 Therapeutics announced the close of a $100 million Series B round , which will be used to advance their regulatory RNA (regRNA)-focused programs. However, in patients with urea cycle disorders, genetic defects result in inadequate amounts of the enzymes needed to convert nitrogen into urea.

RNA 245
article thumbnail

Beyond Covid-19: the disruptive potential of RNA-based therapeutics

Pharmaceutical Technology

Further, the acceptance of new mRNA vaccines has rejuvenated activity within previously established categories of RNA therapeutics including lifesaving antisense technologies. These include antisense oligonucleotides (ASO), RNA interference (RNAi), and RNA aptamers.

RNA 147
article thumbnail

GSK dives into NASH, RNA interference with Arrowhead deal

Bio Pharma Dive

GSK has secured rights to a genetic medicine in early-stage human testing for NASH, a disease thought to affect millions of people and which has proven to be a tough target for drugmakers.

RNA 195